NEWTOWN, Pa.--(BUSINESS WIRE)-- BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, announced that BioClinica WebSend has been included in more than 90% of its 2011 imaging core lab business signings. WebSend benefits clinical trials by speeding access to clinical imaging data while reducing errors and costs by securely sending medical images over the Internet, rather than using courier services.
“The ease of use and resulting high adoption rate by sites have encouraged nearly every one of our top imaging core lab clients to implement this technology,” said Mark Weinstein, CEO of BioClinica. “Unlike alternatives, all of the system capabilities are fully integrated with our core lab processes to streamline the collection, processing, archival and analysis of medical image data. The simplicity and speed of WebSend make the business case direct and compelling.”
WebSend is the most comprehensive solution available for effectively managing electronic image receipt and de-identification from investigator sites. In addition to image transfer, it also includes online viewing of images, web-based reporting for key stakeholders (including trial sponsors), and “cloud-based” image archiving. WebSend integrates with BioClinica onsite image archival and workflow management tools (BioPACS) and read systems (BioREAD) which house imaging reader response data, protocol-specific eCRFs, and more.
“Compared to the history of many other clinical technologies, WebSend adoption is truly dramatic,” said Mr. Weinstein. “WebSend addresses the economic and process improvement pressures that face clinical development with clear and present benefits. It’s an easy choice for most sponsors.”
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.
Jim Dorsey, 267-757-3040
Diccicco Battista Communications
Trade Media – Rachel Summers
Porter, LeVay & Rose, Inc.
Investor Contact - Michael Porter
Financial Media - Bill Gordon
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Technology Data Management Software Health Clinical Trials Medical Devices